mitoxantrone ginsenoside liposome

Mitoxantrone ginsenoside liposome is an experimental antineoplastic formulation developed by Xiamen Ginposome Pharmaceutical. It utilizes the company's proprietary Ginposome Drug Delivery System (DDS), which incorporates ginsenosides (specifically ginsenoside Rg3) into the liposomal membrane as a replacement for or supplement to traditional phospholipids. The active payload, mitoxantrone, is a small molecule antineoplastic agent that acts as a type II topoisomerase inhibitor and DNA intercalator, thereby disrupting DNA synthesis and repair in rapidly dividing cells. This specialized liposomal delivery system is designed to improve the therapeutic index of mitoxantrone, potentially enhancing tumor targeting and reducing systemic toxicities such as cardiotoxicity. While other candidates in the Ginposome pipeline have reached the NDA stage in China, this specific formulation is currently identified in patent materials and lacks public clinical trial data.

Other names

mitoxantrone + ginsenoside liposomeMitoxantrone liposomal formulation (ginsenoside membrane)